Zeolite-fibrin clot composite as a haemostatic agent for haemophilia A

J Biomater Appl. 2019 May;33(10):1427-1433. doi: 10.1177/0885328219832380. Epub 2019 Feb 28.

Abstract

Zeolite is a multifunctional material, which recently exhibited promising prospects in emerging biological and medical applications. This study reported a new bio-inorganic hybrid of zeolite-fibrin clot composite serving as haemostatic agent in haemophilia A. The zeolite-fibrin clot composite promoted haemocompatibility and helped to achieve short clotting time both in vitro (22 ± 3 s vs. >600 s) and in vivo (4.5 min vs. >60 min) compared to control in coagulation factor VIII deficiency bleeding model. Therefore, in situations of surgical operation or accidental injury, this effective and ready-to-use haemostatic agent may provide rapid haemostasis for haemophilia A patients.

Keywords: Zeolite-fibrin clot composite; haemophilia A; haemostatic agent.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biocompatible Materials / therapeutic use*
  • Fibrin / therapeutic use*
  • Hemophilia A / complications
  • Hemophilia A / therapy*
  • Hemorrhage / complications
  • Hemorrhage / therapy
  • Hemostasis / drug effects
  • Hemostatics / therapeutic use*
  • Humans
  • Male
  • Mice
  • Zeolites / therapeutic use*

Substances

  • Biocompatible Materials
  • Hemostatics
  • Zeolites
  • Fibrin